[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT04250259":3,"trial-entities:NCT04250259":127,"trial-summary:NCT04250259":130},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":40,"secondary_outcomes":45,"sex":75,"minimum_age":76,"maximum_age":77,"healthy_volunteers":15,"eligibility_criteria":78,"std_ages":82,"locations":85,"central_contacts":120,"overall_officials":123,"references":125,"see_also_links":126},"NCT04250259","SAMe Trial","SAMe Trial for Patients With Alcoholic Cirrhosis","A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis","RECRUITING","2027-03-01","2026-03","2026-03-31","2020-10-22","Indiana University","OTHER",true,"The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.",null,[19],"Alcoholic Cirrhosis",[21],"Child Class A or B","INTERVENTIONAL","PREVENTION",[25],"PHASE2",{"count":27,"type":28},196,"ESTIMATED",[30,35],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DRUG","Placebo","2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months",[32],{"type":31,"name":36,"description":37,"armGroupLabels":38},"SAMe 400 mg tablet","SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months",[39],"1,200 mg SAMe",[41],{"measure":42,"description":43,"timeFrame":44},"SAMe supplement's effect on all-cause mortality","The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.","Baseline to end of 24 months",[46,50,54,57,60,63,66,69,72],{"measure":47,"description":48,"timeFrame":49},"SAMe supplement's effect on intestinal permeability function, as defined by serum lipopolysaccharides (LPS)","The function of intestinal permeability will be evaluated by testing serum lipopolysaccharides (LPS) in patients who receive SAMe compared to those who receive placebo. Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.","baseline to end of 24 months",{"measure":51,"description":52,"timeFrame":53},"SAMe supplement's effect on cellular oxidative stress and\u002For endoplasmic reticulum (ER) stress, as defined by mitochondrial DNA","Cellular oxidative stress and\u002For endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of mitochondrial DNA in the blood of patients who receive SAMe compared to those who receive placebo.","baseline to 24 months",{"measure":55,"description":56,"timeFrame":53},"SAMe supplement's effect on liver deuteriation","determining Proportion of subjects undergoing liver transplantation in patients who receive SAMe compared to those who receive placebo",{"measure":58,"description":59,"timeFrame":53},"SAMe supplement's effect on liver developing cancer","Proportion of subjects developing new onset hepatocellular carcinoma in patients who receive SAMe compared to those who receive placebo",{"measure":61,"description":62,"timeFrame":53},"SAMe supplement's effect on infections of the liver","Proportion of subjects with infection\u002Fsepsis (other than SBP) in patients who receive SAMe compared to those who receive placebo",{"measure":64,"description":65,"timeFrame":53},"SAMe supplement's effect on other parts of the body","capture safety-related endpoints by determining proportion of patients with nausea and emesis, proportion of subjects with unexplained diarrhea in patients receive SAMe compared to those who receive placebo.",{"measure":67,"description":68,"timeFrame":53},"SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD14","The function of intestinal permeability will be evaluated by testing soluble(s) CD14 in patients who receive SAMe compared to those who receive placebo. sCD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).",{"measure":70,"description":71,"timeFrame":53},"SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD163","The function of intestinal permeability will be evaluated by testing soluble(s) CD163 in patients who receive SAMe compared to those who receive placebo. CD163 is an endocytic receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. As a result of ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163).",{"measure":73,"description":74,"timeFrame":53},"SAMe supplement's effects on cellular oxidative stress and\u002For endoplasmic reticulum (ER) stress, as defined by cytochrome P450 2E1 levels","Levels of cellular oxidative stress and\u002For endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of cytochrome P450 2E1 (CYP2E1) enriched microparticles in patients who receive SAMe compared to those who receive placebo.CYP2E1 is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body.","ALL","18 Years","70 Years",{"inclusion":79,"exclusion":80,"raw_text":81},[],[],"Inclusion criteria for patients with alcoholic cirrhosis\n\n1. Evidence of cirrhosis as per clinical signs and\u002For noninvasive transient elastography (Fibroscan®), computed tomography, magnetic resonance imaging including MRI elastography compatible with cirrhosis and\u002For histopathology by biopsy and\n2. subjects with clinical presentation either in Child Class A or B at the time of enrollment\n3. individuals 18 to 70 years old and may or may not consume alcohol during study.\n\nInclusion criteria for healthy control :\n\n) individuals 18 to 70 years old (2) able to provide informed consent (3) subjects do not consume any alcohol or those who drink \\\u003C 50 grams per day on average in women and \\\u003C 80 grams per day on average in men (4) subjects are healthy without underlying acute or chronic medical conditions.\n\nExclusion criteria for patients with alcoholic cirrhosis\n\n1. Active infection as evidenced by positive urine culture, blood culture, or pneumonia,\n2. Known co-existing infection with hepatitis C, hepatitis B, or HIV\n3. Significant systemic or major illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study\n4. Gastrointestinal bleeding within the prior 28 days3\n5. Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening\n6. Women who are pregnant, may become pregnant, or nursing\n7. Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of SAMe such as those with gastric bypass surgery\n8. Subjects with history of\u002Fdiagnosis of hepatocellular carcinoma\n9. Members from the same family of study participant. This is based on the recent paper on the non-random sampling in randomized controlled trials4. We acknowledge that if we assign family members to identical treatment, randomization would not be totally correct; but if properly randomized, there is a chance that the members of the family might mix the pills. To avoid this issue and maintain the integrity of randomized blinded fashion, we will not include members from the same family into the study\n10. Subjects with psychiatric illnesses such as bipolar disorders as SAMe may interfere with the levels of anti-psychotic drugs and\n11. Subjects who are immunocompromised\n\nExclusion criteria for all healthy control participants:\n\n1. subjects with an active and serious medical disease\n2. subjects with an infectious disease\n3. consume any alcohol within 3 months before the study\n4. subjects with localized or systemic infection",[83,84],"ADULT","OLDER_ADULT",[86,104],{"facility":87,"status":8,"city":88,"state":89,"zip":90,"country":91,"contacts":92,"geoPoint":101},"Cedars-Sinai Medical Center","Los Angeles","California","90048","United States",[93,98],{"name":94,"role":95,"phone":96,"email":97},"Brandon Love","CONTACT","310-423-9917","brandon.love@cshs.org",{"name":99,"role":100},"Shelly Lu, MD","SUB_INVESTIGATOR",{"lat":102,"lon":103},34.05223,-118.24368,{"facility":105,"status":8,"city":106,"state":107,"zip":108,"country":91,"contacts":109,"geoPoint":117},"Indiana University Hospital","Indianapolis","Indiana","46202",[110,114],{"name":111,"role":95,"phone":112,"email":113},"Maggie Hesler, B.S","317-988-4545","mshesler@iu.edu",{"name":115,"role":116},"Suthat Liangpunsakul, MD","PRINCIPAL_INVESTIGATOR",{"lat":118,"lon":119},39.76838,-86.15804,[121],{"name":111,"role":95,"phone":122,"email":113},"(317) 988-4545",[124],{"name":115,"affiliation":13,"role":116},[],[],{"nct_id":4,"conditions":128,"biomarkers":129},[19],[],{"nct_id":4,"found":15,"summary":131,"prompt_version":141},{"design":132,"status":133,"heading":134,"summary":135,"follow_up":136,"word_count":137,"commitments":138,"compensation":139,"drugs_mentioned":140},"This is a randomized, double-blinded, placebo-controlled study, meaning participants will be randomly assigned to receive either SAMe or a placebo, and neither you nor your doctor will know which you are receiving. The study plans to enroll 196 participants.","completed","SAMe Trial for Alcoholic Cirrhosis","This study is testing if a supplement called SAMe (S-adenosylmethionine) can help people with alcoholic cirrhosis (severe scarring of the liver due to alcohol). Researchers want to see if taking SAMe 400 mg tablets, three times a day for 24 months, can improve liver function and reduce the risk of death compared to taking a placebo (an inactive pill). You might be able to join if you are between 18 and 70 years old, have alcoholic cirrhosis, and your liver disease is classified as Child Class A or B. The study aims to enroll 196 participants, but its current status is unclear.","The study will measure all-cause mortality from the beginning of the study to the end of 24 months.",102,"Participants will take either SAMe 400 mg tablets or placebo tablets, two in the morning and one in the evening, for 24 months.","Not stated in the trial record.",[32,36],"v2"]